Cargando…

Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Presti, Elena, Dieli, Francesco, Meraviglia, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228064/
https://www.ncbi.nlm.nih.gov/pubmed/34071430
http://dx.doi.org/10.3390/vaccines9060562
_version_ 1783712654913699840
author Lo Presti, Elena
Dieli, Francesco
Meraviglia, Serena
author_facet Lo Presti, Elena
Dieli, Francesco
Meraviglia, Serena
author_sort Lo Presti, Elena
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had not yet been exploited in depth.
format Online
Article
Text
id pubmed-8228064
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82280642021-06-26 Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities Lo Presti, Elena Dieli, Francesco Meraviglia, Serena Vaccines (Basel) Perspective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had not yet been exploited in depth. MDPI 2021-05-28 /pmc/articles/PMC8228064/ /pubmed/34071430 http://dx.doi.org/10.3390/vaccines9060562 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Lo Presti, Elena
Dieli, Francesco
Meraviglia, Serena
Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title_full Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title_fullStr Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title_full_unstemmed Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title_short Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
title_sort lymphopenia in covid-19: γδ t cells-based therapeutic opportunities
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228064/
https://www.ncbi.nlm.nih.gov/pubmed/34071430
http://dx.doi.org/10.3390/vaccines9060562
work_keys_str_mv AT loprestielena lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities
AT dielifrancesco lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities
AT meravigliaserena lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities